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Abstract – The order Campylobacterales comprises two genera: Campylobacter and Helicobacter, with a widespread distri-
bution in both humans and animals. They are Gram-negative, spiral, helical and microaerophilic bacteria, with an optimal 
growth temperature of 37oC for H. pylori and 42oC for C. jejuni strains. While Helicobacter pylori are restricted to humans, 
other helicobacter species can be found in different mammals and occasionally in humans. Several Campylobacter species 
are recognized as human pathogens, while distinct species are pathogenic only occasionally, in children, the elderly and 
immunocompromised patients. Campylobacters and helicobacters are well adapted to the living conditions inside the gas-
trointestinal tract, where they can cause diseases as a consequence of inflammation. In addition, they are related to certain 
extraintestinal diseases, post-infectious sequels, malignancy and autoimmunity. Different clinical presentations of human 
disorders may be the consequences of the diversity in host immune response, bacterial genome, endotoxin activity as well 
as specific bacterial virulence factors.
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INTRODUCTION
Originally discovered as etiological agents of animal 
diseases,  campylobacters  appear  to  be  one  of  the 
most important human pathogens. Although they 
were initially named vibrios, campylobacters under-
went taxonomic changes until their contemporary 
positioning. At one time, Helicobacter was placed in 
the Campylobacter genus as Campylobacter pyloridis, 
corr.  pylori.  Based  on  extensive  genomic  investi-
gations (Lau et al., 1987; Paster et Dewhirst, 1988; 
Majewski et Goodwin, 1988), the two bacteria were 
finally separated, first as different genera and then as 
distinctive families. Genus Helicobacter G+C content 
is  35-44%  while  G+C  content  of  genus  Campylo-
bacter is 29-38% (Godwin et al. 1989).
Campylobacter – a historical perspective
The end of the 19th century was an important period 
in the development of microbiology, including the 
identification of spiral gastric bacteria. In 1886, Theo-
dor Escherich described a spiral bacteria in the colon 
of children who had died from a disease he termed 
‘cholera infantum’. However, in early days, campylo-
bacter bacteria were not recognized as a cause of di-
arrhea and methods for its successful isolation from 
stool samples were not available for decades. Many 
years later Elisabeth O’King who understood their 
importance, insisted on the development of specific 
cultivation techniques. “Unfortunately, such a meth-
od was not developed in her lifetime, but her vision 
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In the 40 years after their recognition, campylo-
bacters were referred only to veterinary medicine. In 
1947, Vinzent for the first time published data on vi-
brio isolation from the blood of 3 pregnant women 
with fever of unknown etiology, which in two cases 
ended with abortions (Vinzent et al., 1946). Before 
that report, in May in 1938, Illinois, USA, the first 
well-documented  human  campylobacter  infection 
occurred. It was a diarrhea outbreak caused by milk 
consumption. Fecal culture was negative in all pa-
tients while in 31 patients the presence of bacteria 
resembling ‘V. jejuni’ was detected microscopically. 
In  13  patients,  this  microorganism  was  recovered 
from the blood stream (Levy, 1946). 
All species that belong to the genus Campylo-
bacter, as well as related taxa, in 1991 were classi-
fied in the same phylogenetic group, rRNK super-
family VI. At that time, the genus Campylobacter was 
comprised of 15 species (Vandamme et al., 1991). 
Contemporary  taxonomy  described  these  micro-
organisms as members of the following categories: 
Kingdom:  Bacteria,  Phylum:  Proteobacteria,  Class: 
Epsilonproteobacteria,  Order:  Campylobacterales, 
Family Campylobacteraceae, Genera: Campylobacter 
and Arcobacter. Nevertheless, constant scientific ef-
forts are revealing novel campylobacter species and 
candidates: C. avium (poultry) C. canadensis (Grus 
americana), C. cuniculorum (rabbits), C. hominis (hu-
mans), C. insulinegria (sea mammalian), C. lanienae 
(workers  at  abattoirs),  C.  peloridis,  Campylobacter 
lari-like  strains  (shellfish  and  humans),  Campylo-
bacter troglodytis (human) (Euzéby, 2011).
Clinical presentations of Campylobacter infections
At least 12 species of campylobacters can cause dis-
ease in humans, but major credit belongs to the ther-
mophilic organisms: Campylobacter jejuni, Campy-
lobacter coli, Campylobacter lari and Campylobacter 
upsaliensis. These are etiological agents of diarrhea in 
4-15% of all age groups. Diarrhea can be bloody, with 
cramps  and  abdominal  pain.  In  immunocompro-
mised patients, Campylobacter can enter the blood 
stream and cause life-threatening infections. Campy-
lobacter are more frequently isolated in children and 
young  adults  than  in  other  age  groups.  Although 
most infections are mild and self-limiting, resolving 
within a few days without antibiotic treatment, se-
vere or prolonged infections can occur in the young, 
elderly and in individuals with compromised immu-
nity (Blaser, 1997; Blaser et Reller, 1981).
The consequences of infection can be extrain-
testinal manifestations such as transient bacteremia, 
localized infections including septic arthritis, men-
ingitis (Blaser, 1997), peritonitis (Van den Enden et 
al., 1990), cholecystitis (Drion et al., 1988), hepati-
tis (Braun et al., 2008), pancreatitis (De Bois et al., 
1989), abscesses, fulminate sepsis (Blaser et Reller, 
1981, Fernández-Cruz et al.,2010). Several cases of 
myocarditis as a complication of C. jejuni infection 
have been reported (Braun et al., 2008, Kratzer et al., 
2010). As an effect of Campylobacter enteritis, hemo-
lytic uremic syndrome can occur (Bruce et al., 1983). 
Long-term  repercussions  of  campylobacter  infec-
tion are Guillain-Barré syndrome (GBS) (Miljković-
Selimović et al., 2010), or a variant of GBS, Miller 
Fisher  syndrome  (MFS)  (Willison  et  Yuki,  2002), 
musculoskeletal disorders (Hannu et al., 2002), in-
flammatory bowel disease (IBD) (Garcia Rodriguez 
et al., 2006, Kalischuk et al., 2010] and immunopro-
liferative small intestinal disease (IPSID) (Lecuit et 
al., 2004). 
In  campylobacter  intestinal  infections,  signifi-
cant roles are assumed by a variety of  adhesion fac-
tors (Campylobacter adhesion to fibronectin (CadF), 
fibronectin-like protein A (FlpA), Campylobacter ad-
hesion protein A (CapA), Jejuni lipoprotein A (Jlpa), 
periplasmatic  protein,  Pei,  Ellison,  Blaser  (PEB), 
Cj496c, major outer membrane protein, (MOMP), 
capsular polysaccharide (CPS), lipooligosaccharide, 
(LOS)),  invasiveness  (Campylobacter  invasive  pro-
teins (Cia) proteins), toxicity (cytolethal distending 
toxin  -  CDT),  genetic  variability  (Nielsen,  2010), 
biofilm formation (Reuter et al., 2010) and quorum 
sensing (Elvers et Park, 2002). C. jejuni is the first and 
almost unique prokaryote that contains both O- and 
N-linked glycosylation systems. Studies investigat-
ing the biological role of N-linked glycosylation con-
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while O-linked glycosylation has been essential for 
successful flagellin assembly and motility, adhesion, 
invasion and virulence in vivo (Guerry et al., 2006). 
Based on clinical syndromes, two mechanisms 
by  which  Campylobacter  can  induce  disease  were 
postulated: adherence of Campylobacter to the intes-
tine and toxin production that alters the fluid resorp-
tion capacity of the intestine, resulting in secretory 
diarrhea or bacterial invasion and replication within 
the intestinal mucosa accompanied by an inflamma-
tory response resulting in blood-containing, inflam-
matory diarrhea (Janssen et al., 2008). 
C.  jejuni  bacteria  initially  colonize  the  small 
bowel and then move to the colon which is the target 
organ. These bacteria can adhere to epithelial cells 
via a number of different adhesions, but the relative 
significance  of  each  to  disease  remains  uncertain. 
JlpA is a surface exposed lipoprotein that has been 
shown  to  bind  to  the  surface-exposed  heat  shock 
protein Hsp90a on Hep-2 epithelial cells resulting in 
the activation of NF-kB and p38 mitogen-activated 
protein kinase (MAPK). CadF mediates adhesion by 
binding to the cell matrix protein, fibronectin. This 
protein has recently been shown to be critical in the 
activation of Rac1 and Cdc43 in INT407 cells. An-
other reported adhesion is PEB1, a periplasmic ABC-
binding protein that binds aspartate and glutamate 
and that is required for the intestinal colonization 
of mice. More recently, a putative autotransporter, 
CapA, has been described that also plays a role in the 
adherence and invasion of Caco-2 cells in vitro (Poly 
et Guerry, 2008).
The flagella filament of Campylobacter appears to 
function as a type III secretion organelle that secretes 
a number of proteins. The Cia proteins are secreted 
through the flagella filament upon contact with a eu-
karyotic cell or a signal from the eukaryotic cell. In-
vasiveness is promoted by the bacterial ability to dis-
rupt the tight junctions of epithelial cells. The ability 
to break the epithelial cell barrier either via transcel-
lular (through epithelial cell invasion) or paracellular 
(via tight junctions) routes allows the bacterium to 
move to the basolateral surface and either reinvade 
the epithelial cell or be taken up into macrophages. 
C. jejuni can replicate intracellularly in macrophages 
and induce apoptosis (Poly and Guerry, 2008).
It has been demonstrated that C. jejuni infection 
activates intestinal epithelial NF-κB (Zilbauer et al., 
2005) and that the surface protein JlpA promotes 
bacterial adhesion leading to NF-κB and p38MAP 
kinase  activation.  The  crucial  mediators  of  inter-
leukin (IL)-8 production are C. jejuni adhesion/in-
vasion and the presence of CDT. IL-8 induction can 
be provided by an ERK pathway, while ERK and p38 
MAP kinases are involved in C. jejuni-mediated host 
responses (Watson et al., 2005). It is possible that hu-
man-pathogen interaction can be fulfilled by patho-
gen associated molecular patterns (PAMPs), which 
interact with toll-like receptors (TLRs), a form of 
host pattern recognition receptor (PRRs) (Sander-
son et al., 2007). Nucleotide oligomerization domain 
1 (NOD1), a cytoplasmic, intracellular PRR, is high-
lighted as a major PRR involved in C. jejuni-medi-
ated epithelial responses (Zilbauer et al., 2007). An 
important protective role during C. jejuni infection 
is played by the antimicrobial peptides β-defensins 
(Zilbauer et al., 2005). These molecules damage the 
structure of C. jejuni, potentially contributing to the 
enhanced bacterial clearing and self-limiting nature 
of disease in immunocompetent patients (Zilbauer et 
al., 2005; Zilbauer et al., 2009). 
Although  Campylobacter  can  circumvent  the 
activation of innate immunity via TLR5 and TLR9, 
innate immune mechanisms are essential for host 
defense,  since  mice  defective  in  downstream  TLR 
signaling  and  NFκB-gene-deleted  mice  display  an 
enhanced susceptibility to Campylobacter infection 
(Janssen et al., 2008) 
In  the  etiology  of  neurological  postinfectious 
sequels (such as GBS), the molecular mimicry be-
tween C. jejuni LOS and human gangliosides, de-
scribed by Yuki and co-workers (Yuki et al, 1993), 
is of paramount importance in the genesis of cross-
reactive  antibodies  and  initialization  of  autoim-
mune response. In addition, it has been shown that 
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involved in sialylation are important for the gan-
glioside mimicry and the induction of antiganglio-
side antibodies (Godschalk et al., 2004; Godschalk 
et al., 2007). Preceding C. jejuni infection is often 
caused  by  serotype  O:19  (Miljković-Selimović  et 
al., 2010). Other serotypes also associated with GBS 
are: O:41, O:1, O:2, O:4, O:4 complex (4, 13, 16, 43, 
50), O:5, O:10, O:16, O:23, O:37, O:44, O:64 O:35 
and O:13/65 (51). Miller Fisher syndrome (MFS), 
which is characterized by ophthalmoplegia, ataxia 
and areflexia, can be related to C. jejuni O:10 and 
O:2.  Conditions  related  to  MFS  are  Bickerstaff’s 
brainstem  encephalitis  (BBE);  acute  ophthal-
moparesis;  ataxic  GBS;  and  pharyngeal-cervical-
brachial (PCB) weakness (Willison et Yuki, 2002). 
Some authors consider PCB, GBS, MFS and BBE 
to be forms of a continuous spectrum (Nagashima 
et al., 2007). Thus, besides neurological examina-
tion,  specific  microbiological  and  immunological 
tests are necessary in the etiological diagnosis of C. 
jejuni neurological postinfectious sequels. In addi-
tion, clinical, epidemiological and microbiological 
investigations are warranted in C. jejuni characteri-
zation and HS serotypes prevalence investigation in 
GBS etiology as well as in etiology of other post-
infectious sequels. 
C. jejuni is also associated with post-infectious 
musculoskeletal  manifestations:  reactive  arthritis 
(ReA), sacroiliitis, enteropathic spondylitis, and un-
differentiated spondylitis. Symptoms of reactive ar-
thritis usually occur around 14 days after infection 
(range, 3 days to 6 weeks). Some investigations re-
vealed that the percentage of patients with confirmed 
C.  jejuni  infection  who  develop  ReA  range  from 
0.7%, (1.8%, 2.0%, 2.6%, 7%,) to 30% (Ristić, 2010). 
A population study in southern Finland found that 
7% of the participants developed ReA and 1% de-
veloped reactive tendinitis, enthesopathy or bursitis 
(Hannu et al., 2002). Investigation of patients with 
ReA showed that 24% (Mäiki-Ikola et al., 1991) or 
63% (Soderlin et al., 2002) had antecedent Campy-
lobacter infection. Several events participate in the 
immunopathogenesis of musculoskeletal disorders: 
a long-term production of IgA directed towards bac-
terial agents; diminished reactivity of peripheral T 
lymphocytes to bacterial antigens from the digestive 
tract; chronic stimulation in the enteric lymphatic 
tissue  provoked  by  bacterial  antigens;  survival  of 
bacteria and its penetration into circulation enabled 
by weakened T cell defense (Toivanen and Toivanen, 
2001). The association and role of HLA B27 are still 
vague, but several experimental models have been 
proposed for the pathogenesis of ReA (Marker-Her-
mann, 1998). 
C. jejuni has been isolated from patients with IBD 
such as Crohn’s disease (CD) and in patients with ir-
ritable bowel syndrome. C. jejuni enteric infection 
results in damage of the mucosal layer and distur-
bance in normal bacterial gut flora, which could lead 
to illness. It is possible that bacterial toxicity plays a 
leading role (Janssen et al., 2008). As IBD patients 
exhibit inflammatory responses to their commensal 
intestinal  microflora,  translocation  of  commensal 
bacteria across the intestinal epithelium may con-
tribute to IBD pathogenesis. C. jejuni, regardless of 
its own invasiveness, promotes the translocation of 
noninvasive bacteria across the intestinal epithelium 
via a lipid raft-mediated transcellular process (Kalis-
chuk et al,. 2009). In addition, C. jejuni may utilize M 
cells for the transcytosis promotion of non-invasive 
bacteria (Kalischuk et al., 2010). C. jejuni infection 
concomitant with intestinal inflammation and expo-
sure to interferon gamma (IFN)-γ would result in an 
intensive bacterial translocation across the intestinal 
epithelial monolayer, rapid loss of epithelial barrier 
integrity, which may be a key event in the pathogene-
sis of C. jejuni-mediated colitis and the development 
of bloody diarrhea (Rees et al., 2008). Not only C. 
jejuni, but also C. concisus, C. showae, C. hominis, C. 
ureolyticus, C. hyointestinalis, C. rectus, and C. graci-
lis, are described risk factors for the development of 
IBD through unknown mechanisms in adult patients 
with CD (Mahendran et al., 2011). In children with 
CD, the presence of Campylobacter species other than 
C. jejuni has also been detected: there was a signifi-
cantly greater presence of C. concisus and antibodies 
to C. concisus in patients than in the control (Zhang 
et al., 2009). Nevertheless, a causal link between the 
bacterium  and  the  pathogenic  mechanisms  of  in-
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An association between C. jejuni infection and 
irritable bowel syndrome was also observed. These 
enteric infections result in mucosa damage and dis-
ruption of the native gut flora, which could lead to 
prolonged bowel dysfunction. Increased enteroendo-
crine cells, T lymphocytes and gut permeability are 
acute changes following Campylobacter enteritis that 
can persist for more than a year and may contrib-
ute to post-diarrheal irritable bowel syndrome (PB-
IBS) (Spiller et al., 2000). In addition, the long-term 
symptoms that occur in Campylobacter infection are 
significantly associated with bacterial toxicity on the 
cell culture (Thornley et al., 2001).
Since C. jejuni association with IPSID has been 
confirmed, it seems that C. jejuni can be considered 
as a possible candidate responsible for immunopro-
liferative states (Lecuit et al., 2004). The role of C. je-
juni in IPSID may be similar to that played by H. py-
lori in gastric MALT lymphoma. The lymphoma cells 
synthesize defective α heavy chains as a response to 
tissue autoantigens. The uncontrolled autoantigenic 
stimulus  results  in  a  continuous  differentiation  of 
lymphoma cells into atypical plasma cells, while the 
removal of the bacterial T-cell stimulus inhibits the 
proliferation of lymphomatous B cells (Parsonnet et 
al., 2004).
Antimicrobial  therapeutic  intervention  is  war-
ranted  in  severe  forms  of  disease,  extraintestinal 
manifestations and in post-infective sequels (Blaser 
et  Engberg,  2008).  However,  antibiotic  interven-
tion in food-producing animals in therapy, disease 
prevention and as growth promoters, has generally 
introduced problems of resistance in thermophilic 
campylobacter  species.  Resistance  is  an  increas-
ing  problem,  especially  against  fluoroquinolones, 
tetracyclines and macrolides, the drugs applied in 
diarrhea  therapy.  In  one  investigation  of  Serbian 
strains, gentamicin and chloramphenicol sensitivity 
was 100%, while resistance to erythromycin, tetra-
cycline, ciprofloxacin and nalidixic acid occurred in 
2.4%, 9.9%, 29.8% and 33.3% of strains, respectively. 
Resistance to tetracycline and especially ciprofloxacin 
emphasizes the need for continual sensitivity testing. 
(Miljković-Selimović et al., 2009).
Detection and strain characterization
Although biochemical tests are commonly applied 
in the identification of thermophilic campylobacters, 
their identification power is restricted to specific bi-
ochemical pathway expression in particular strains. 
Thus, PCR and PCR-based methods are considered 
to be a valid and reproducible approach for the de-
tection of hipO, glyA, asp, ceuE, cad, fur, cdtABC, 
ceuB-E, fliY and other genes (Volokhov et al., 2003; 
Kabir et al., 2011; Persson and Olsen, 2005).
Phenotypic  characterization  of  strains  can  be 
performed by biotyping and serotyping. The biotyp-
ing of C. jejuni and C. coli includes hippurate hydrol-
ysis, H2S and DNase production, while serotyping is 
based on heat labile (HL serotyping) and heat stabile 
antigens  (HS  serotyping).  Investigation  of  the  HS 
and HL serotypes of C. jejuni and C. coli isolated in 
Serbia, confirmed their clonal diversity, with no pre-
dominant ones (Miljković-Selimović et al., 2010). 
Current  typing  methods  are  usually  based  on 
molecular techniques: pulse field gel electrophoresis 
(PFGE), amplified fragment length polymorphism 
(AFLP),  flagellin  gene  restriction  fragment  length 
polymorphism  analysis  (flaA-RFLP),  multi  locus 
sequence  typing  (MLST),  multiple-locus  variable 
number tandem repeat analysis (MLVA), and DNA 
Microarray with comparative genomic hybridization 
(CGH) (Wieland, 2006). The existence of a strong as-
sociation of genotypes with particular hosts is noted, 
and is greater than the geographic signal. These find-
ings are consistent with local and international trans-
mission of host-associated lineages of Campylobacter 
among food animal species (Sheppard et al., 2009).
To  understand  the  molecular  mechanisms  in-
volved  in  C.  jejuni  adaptation  to  its  environment 
(oxidative stress, temperature, biofilms), innovative 
technologies,  including  proteomic,  transcriptomic, 
lipidomic and genomic approaches, are needed (Seal 
et al., 2007). Still, little is known regarding the role 
of individual proteins in virulence: adhesion, colo-
nization and toxicity, bacterial response to changes 
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lar locations of most proteins. C. jejuni, unlike most 
other bacteria, is able to modify post-translationally 
proteins, the analysis of which represents a challenge 
in understanding this organism at the proteomic and 
cellular levels (Scott and Cordwell, 2009). Proteom-
ics are also useful for characterizing phenotypic vari-
ation among Campylobacter spp. isolates. The differ-
ent gene products potentially involved in the robust 
colonization of chickens by Campylobacter spp. ap-
pear  to  conform  to  recently  identified  expression 
patterns in biofilm or agar-adapted isolates (Seal et 
al., 2007).
Helicobacter discovery
The  gastric  spiral  bacteria  were  first  described  in 
1893 when Bizzozero, an Italian pathologist, discov-
ered helical bacteria in the canine stomach. In 1896, 
Salomon reported similar findings in the stomachs of 
cats and mice. The presence of spiral bacteria in the 
human gastric system was detected in 1906, where, 
for the first time, Krienitz observed these organisms 
in patients with gastric carcinoma. Nine years later, 
Rosenow and Sanford found spiral microorganisms 
in the stomachs of patients with gastric and duodenal 
ulceration (Buckley and O’Moraint, 1998). The mod-
ern era in H. pylori investigation began with the Mar-
shall and Warren H. pylori research (Marshall and 
Warren, 1984) in humans, and with their tenacity in 
changing the dogma of ulcer disease etiology which 
finally led to the revision of medical text books. 
The  genus  Helicobacter  was  described  in  1989 
(Goodwin et al., 1989) and with Wolinella species 
belongs  to  the  family  Helicobacteraceae.  Members 
of the genus can be classified in gastric and entero-
hepatic Helicobacter taxa. Based on 16S rRNA se-
quences, the phylogenetic tree is represented with 18 
validated Helicobacter species, two candidate species, 
and nine additional provisional species (Solnic and 
Vandamme. 2001). H.  baculiformis is the last for-
mally named Helicobacter species isolated from the 
stomach of a cat (Baele et al., 2008). H. callitrichis 
and H. macacae are other isolates that have not been 
validated so far, but that are likely to represent a new 
helicobacters (Moyaert et al., 2008).
Helicobacter species characterized in the last dec-
ade are H. anseris (goose), H. aurati (golden Syrian 
hamster), H. baculiformis (feline stomach mucosa), 
H. brantae (geese), H. canadensis (humans), H. ce-
torum  (whales,  dolphins),  H.  cynogastricus  (ca-
nine gastric mucosa), H. equorum (horse feces), H. 
ganmani (laboratory mice), H. marmotae (livers of 
woodchucks and intestines of cats), H. mastomyrinus 
(liver and intestine of rodents), and H. suis (pig), H. 
typhlonius (murine)  (Euzéby, 2011).
It is assumed that H. pylori spread from East Af-
rica over the same time scale (58,000 years ago) as 
modern humans. Studies have confirmed that H. py-
lori had colonized human gaster before modern man 
left his cradle, since genetic diversity in H. pylori de-
creases with geographic distance from East Africa. In 
addition, bacterium and man had similar evolution 
patterns, following human migration from East Af-
rica to Asia, and the neighboring regions: Oceania, 
Europe and America (Vale et al., 2009). The map of 
H. pylori strain diversity appears to be similar to that 
of humans (Covacci et al., 1999, Linz et al., 2007). 
Differences among the strains were followed at 
the genomic level for detection of their geograph-
ic  distribution.  The  H.  pylori  rpoB  gene  (coding 
RNA polymerase β subunit) presents allelic diver-
sity between Asian and non-Asian strains (Lee et 
al., 2004). Moreover, allelic diversity according to 
the geographic distribution was found for the babA 
and babB genes (coding outer membrane proteins) 
(Pride and Blaser, 2002; Pride et al, 2001). The trans-
posable element ISHp60 is also represented non-
randomly with higher frequency in Latin America 
and lower in East Asia (Kersulyte et al., 2002). The 
hopQ (omp27) alleles additionally show high genet-
ic variability: type I alleles from Western and Asian 
H. pylori strains were similar and markedly differ-
ent from type II hopQ, which were frequently iden-
tified in Western H. pylori strains, but rarely in East 
Asian strains (Cao et al., 2005). Furthermore, the 
geographic distribution of H. pylori methyltrans-
ferases  gives  evidence  of  human  host  population 
isolation  and  migration  (Vale  et  al.,  2009)  along 
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iceA, that also cluster in strains of particular geo-
graphic regions (Li et al., 2002). 
Helicobacter capability to persist in the human 
niche for thousands of years may be attributed to the 
predicted versatile horizontal and vertical transmis-
sion routes and diversity of plausible reservoirs and 
sources.  Thus,  H.  pylori  transmission  pathways  in 
developing rural and developed urban areas appear 
to be different. In developed areas, person-to-person 
transmission within families may be dominant, while 
in the developing areas the transmission is probably 
much more complex. In rural areas, the transmission 
by contaminated food, water, or via intensive contact 
between  infants  and  non-parental  caretakers  may 
have a greater influence than within family transmis-
sion (Vale and Vítor, 2010).
Although, H. pylori isolation in humans was 
intense  in  2003  and  2004,  there  were  two  out-
breaks of increased mortality associated with gas-
tric bleeding and weight-loss in a captive colony of 
the Australian marsupial, the stripe-faced dunnart 
(Sminthopsis macroura). Histological examination 
revealed the presence of gastritis, and PCR analysis 
confirmed the presence of H. pylori infection in the 
stomachs of these marsupials. It was confirmed that 
the strain was positive for the important pathogen-
esis factor, cagA. For the first time an apparent re-
verse zoonotic infection of animals with H. pylori 
was  described.  Indeed,  H.  pylori  spontaneously 
vanished from the animal population (Every et al., 
2011).
H. pylori in the etiology of gastrointestinal diseases
Although,  H.  pylori  colonizes  the  human  gaster 
in  approximately  half  of  the  human  population, 
it causes  persistent inflammation  with  symptoms 
only  in  a  subgroup  of  patients  (Ernst  and  Gold, 
2000). An even smaller proportion of infected per-
sons develops severe diseases, such as peptic ulcers, 
gastric MALT lymphoma or gastric carcinoma. Nu-
merous studies have demonstrated the phenotypic 
and genotypic diversity in H. pylori strains, which is 
responsible for different types of inflammatory re-
sponses in the host as well as versatile clinical out-
comes (Kusters et al., 2006).
H. pylori in non-malignant gaster diseases
Non-malignant  diseases  associated  with  H.  pylori 
infection are gastritis, peptic ulcer, gastroesophageal 
reflux disease, gastric polyps, nonsteroidal-anti-in-
flammatory drug⁄aspirin-induced gastric injury and 
functional dyspepsia (Furuta et Delchier, 2009). 
The defined virulence factors of H. pylori are 
cytotoxin-associated  gene  pathogenicity  island 
(cagPAI),  vacuolating  cytotoxin  (VacA),  adhesion 
factors and outer membrane proteins (blood group 
antigen  binding  adhesion  (BabA  or  HopS)),  outer 
inflammatory protein adhesion (OipA), sialic acid-
binding adhesion (SabA or HopP) and lipopolysac-
charides (LPS) (Kusters, 2006). 
In the host, H. pylori induces both innate and 
specific  immune  responses,  which  in  turn  deter-
mines  the  infection  outcomes.  The  humoral  im-
mune response does not have a protective role in H. 
pylori infection, while cell immunity predominates 
and protects from diseases. Innate epithelial defense 
depends on TLR and NOD-like receptor (NLR) activa-
tion which induces a H. pylori specific T helper (Th)1 
immune response. Innate epithelial defense of gastric 
mucosa from H. pylori infection depends on TLR 
and NLR activation, which is responsible for a H. 
pylori specific Th1 immune response. Infiltration of 
the gastric mucosal layer with inflammatory cells is 
a frequent finding in H. pylori infection. The degree 
of mucosal damage is in correlation with neutrophile 
infiltration. It seems that the H. pylori neutrophile 
activating protein (HP-NAP) is the key factor in the 
generation of Th1 response and interleukin synthesis 
in monocytes, dendritic cells, and neutrophiles by 
TLR2 activation. Although bacterial LPS of Gram-
negative pathogens recognizes TLR4 on the surface 
of epithelial cells, H. pylori LPS activates TLR2 rather 
than TLR4, thus activating NF-κB (Del Giudice et al., 
2001). H. pylori flagella cannot activate the TLR5 re-
ceptor (Andersen-Nissen et al., 2005), also vacA does 
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of  innate  immune  recognition  mediated  by  TLR4 
or TLR5 (Garza-González et al., 2008). In H. pylori 
infection and Th1 activation, the synthesized proin-
flammatory cytokines are IFN-γ, IL-12, IL-18 and 
tumor necrosis factor (TNF)-α. The degree of gastri-
tis intensity is in correlation with TNF-α and IFN-γ 
expression. Peptic ulceration is associated with H. 
pylori specific local gastric Th1-cell responses (Berg-
man et al., 2006). A strong Th1 mucosal response is 
associated  with  the  progression  of  gastric  mucosa 
damage, occurrence of atrophic gastritis and gastric 
adenocarcinoma (Kusters et al., 2006).
On  the  contrary,  in  the  subgroup  of  patients 
with asymptomatic chronic gastritis who fortunately 
account for the 80-90% of individuals infected but 
without  apparent  disease,  most  H.  pylori-specific 
gastric T cells are Th0 cells, which secrete both Th1 
and Th2 cytokines such as IFN-γ and IL-4 (D’Elios 
et al., 1997). Thus, data obtained from humans in-
dicate that H. pylori-infected individuals who can 
overcome the initial Th1-cell-dominated response, 
mount a mixed Th1- and Th2-cell response to H. py-
lori in their gastric mucosa, which maintain persist-
ent colonization without developing clinical disease 
(Bergman et al., 2006). This indicates that most in-
fected people switch from an acute gastric H. pylori-
specific response mediated by Th1 cells, to a response 
that is mediated by Th1 and Th2 cells. It seems that 
the H. pylori phase variants that bind C-type lectin 
that is a cell-surface receptor on dendritic cells (DC-
SIGN),  suppress  the  development  of  Th  cells  into 
Th1 cells through IL-10 (Bergman et al., 2004). This 
event might facilitate the switch and be selected by 
the host. DC-SIGN-binding variants of H. pylori are 
selectively bound by DC-SIGN-expressing DCs that 
protrude from the gastric epithelium, and these cells 
subsequently  migrate  to  the  gastric  lymph  nodes, 
where they suppress the development of Th cells into 
Th1 cells (Bergman et al., 2006).
Increased regulatory T cell (Treg) activation by 
bacterial antigens is one of the defense mechanisms 
of H. pylori that enable bacterial immune evasion 
from  host  immunity.  Treg  suppress  antibody  re-
sponse and T-cell response either by cell contact or 
by TGF (transforming growth factor)-ß and IL-10. 
H. pylori gastritis is associated to Treg accumulation. 
In peptic ulcer disease, elevated Treg secreting IL-10 
in gastric mucosa control the inflammation enabling 
bacterial  persistence  in  gastric  mucosa.  Treg  cells 
have a protective role for mucosa from extensive gas-
tric inflammation on one hand, while on the other, 
they stimulate the gastric colonization and persist-
ence of H. pylori infection (Kusters et al., 2006).
H. pylori in malignant gaster diseases
The role of H. pylori in human malignant diseases 
is at present undisputable. The International Agency 
for Research on Cancer has classified H. pylori as a 
class I carcinogen (IARC 1994). Nevertheless, tumor 
progression occurs only in a subset of individuals and 
depends on the host response as well as genetic vari-
ation of the bacteria. H. pylori virulence factors are 
key features in carcinogenesis. All H. pylori strains 
possess the vacA gene, but not all of them induce 
vacuolation. Two major polymorphic regions of the 
vacA gene are the signal region (s1 or s2) and the 
mid-region (m1 or m2). Malignancy is associated 
with s1/m1 strains and some s1/m2 strains. Rhead 
and associates identified a new vacA polymorphic 
site, designated as the intermediate (i) region, and 
two sequence types (i1 and i2). It was shown that 
s1/m1 and s1/m2 strains were exclusively i1 and s2/
m2 exclusively i2. Only the i region was determined 
to be an independent marker of gastric carcinoma 
(GC). The typing of the i region may be sufficient for 
the identification of all pathogenic forms of vacA and 
may be very useful in cancer prevention (Rhead et 
al., 2007).
The  host  genetic  factors  that  drive  immune 
mechanisms have great significance in carcinogen-
esis. A high level of pro-inflammatory cytokine IL-1 
expression (IL-1β) and upregulation of IL1RN (which 
encodes the receptor antagonist of IL-1β) consecu-
tively  decrease  gastric  acid  secretion  and  increase 
the risk for atrophic gastritis. These events associated 
with predominant corpus H. pylori colonization and 
pangastritis, occur in individuals with a rise in the 
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et al., 2002). In addition to IL-1 gene-cluster poly-
morphisms, in TNF-α a pro-inflammatory cytokine, 
genotype TNF-A 308A, is associated with augmented 
TNF-α production and the increased risk of gastric 
carcinogenesis  associated  with  H.  pylori  infection 
(El-Omar et al., 2003).
Expression  of  the  anti-inflammatory  cytokine 
IL-10  is  determined  by  certain  IL-10  gene  haplo-
types: haplotype GCC is associated with an elevated 
expression of IL-10, and thereby with an enhanced 
anti-inflammatory  response.  Haplotype  ATA  de-
creases the level of IL-10 favoring the pro-inflam-
matory response (Kusters et al., 2006). An increas-
ing number of pro-inflammatory genotypes seem to 
increase progressively the risk of gastric cancer: the 
presence of three to four specific pro-carcinogenic 
polymorphisms increases the risk of gastric cancer 
27-fold compared to an absence of these haplotypes 
(El-Omar et al., 2003). Thus, the development of H. 
pylori-associated pathology is correlated with the ra-
tio of Th1 and Th2 subsets, and the pro- and anti-
inflammatory responses are influenced by the geno-
types of the host (Bergman et al., 2006).
Changes in epithelial cell signaling induced by 
H. pylori contribute to the gastric carcinogenic proc-
ess. A combination of CagA-dependent and CagA-
independent signaling, which is dependent on the 
bacteria type IV secretion system (TFSS) mediated 
by Jun N-terminal kinase (JNK) activation through 
β1-integrin and Src, was required to stimulate can-
cer cell motility (Snider et al., 2008). Although both 
pathways are necessary, neither is sufficient by itself 
to alter the phenotype. The Cag A-independent sig-
naling that occurs through the TFSS indicates that 
TFSS may play a more important role in host cell 
physiology than just the delivery of CagA from the 
bacterium into the host cell cytoplasm (Ferreira et 
al., 2008). Apoptosis, the process of cell-destruction, 
may be under the influence of the genotype of the 
infecting bacteria. Although H. pylori cagPAI-nega-
tive strains can induce this process, the expression 
of cagPAI promoted apoptosis more rapidly and in-
creased DNA fragmentation in gastric epithelial cells 
(Minohara et al., 2007). The major H. pylori-induced 
apoptotic pathway in gastric cancer cells requires the 
activation of caspases-3 and -9 (Zhang et al., 2007). 
H. pylori also impairs the E-cadherin and β-catenin 
cell adhesion complex, leading to aberrant activa-
tion of β-catenin in an animal model, and thus is 
involved in precancerous intestinal metaplasia pro-
gression. It was noted that the gene that encodes for 
β-catenin can function as an oncogene (Wang et al., 
2008), and the increase in β-catenin production was 
recorded in people with some forms of carcinoma 
(Saldanha et al., 2004). In addition, matrix metal-
loproteinases (MMPs) are a family of nine or more 
highly homologous zinc-dependent endopeptidases 
that collectively cleave most if not all of the constitu-
ents of the extracellular matrix (Birkedal-Hansen et 
al., 1993). They have the potential to disrupt gastric 
stroma and to promote bacterial invasion. In MMP 
secretion, CagA-dependent and CagA-independent 
mechanisms  are  involved.  In  addition  to  the  dys-
regulation of β-catenin production by the CagA-de-
pendent mechanism, it was shown that CagA, and in 
particular the EPIYA motif, was required for optimal 
extracellular signal-regulated kinase (ERKs) activa-
tion and MMP-1 secretion (Ferreira et al., 2008). 
In  addition  to  genetic  alterations,  epigenetic 
changes  are  also  involved  in  cancer  development 
and progression. H. pylori infection may be linked to 
CpG (cytosine-phosphate-guanine sites) hypermeth-
ylation, a mechanism that is particularly relevant in 
cancer since it can interfere with the expression and 
activity of tumor suppressor genes. Consequently, the 
rates of promoter methylation of p16, E-cadherin, 
and death-associated protein kinase are significantly 
higher in the noncancerous gastric mucosa of gastric 
cancer patients (Kaise et al., 2008).
In the characterization of host immune response 
to  cagA+ H.  pylori  infection,  the  association  with 
Th1-mediated cellular immunity in earlier stages of 
GC was observed with a shift to the Th2-mediated 
humoral immunity in the advanced stages. When 
stimulated by H. pylori, T cells from GC patients pro-
duced high amounts of IL-10, an inhibitory cytokine 
of Th2 immune response. This production was low in 
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was proposed that the increased production of sup-
pressive cytokine IL-10 in H. pylori-infected GC pa-
tients might lead to a decreased cytotoxic antitumor 
T-cell response in the stomach, which may contrib-
ute to tumor progression (Ferreira et al. 2008). 
In gastric MALT lymphoma, CD4+T cells that 
encounter the H. pylori antigens displayed by anti-
gen-presenting  cells  stimulate  the  proliferation  of 
neoplastic B cells. These B cells synthesize IgM, IgA, 
or IgG autoantibodies and differentiate to varying 
degrees into mature plasma cells (Parsonnet et al., 
2004). Although gastric mucosa does not normally 
contain lymphoid tissue, MALT appears in response 
to colonization with H. pylori. In some cases, a mono-
clonal population of B cells may arise from this tissue 
and slowly proliferate to form a MALT lymphoma. 
In particular, diagnosis is based on histological ap-
pearance during routine microscopy and on dem-
onstration  of  clonality  by  immunohistochemistry 
or molecular techniques, such as PCR. A major pre-
dictor for MALT response appears to be a particular 
translocation  that  is  associated  with  API2-MALT1 
fusion. Translocation t(11;18)(q21;q21) generates a 
functional API2 (apoptosis inhibitor 2)-MALT1 fu-
sion transcript (Ferreira et al., 2008). The former is 
involved in regulation of apoptosis, while the latter 
resembles a caspase-like protein. Together, the fu-
sion leads to suppression of apoptosis (Kusters et al., 
2006).
Extragastric manifestations of H. pylori infection
Extragastric manifestations of H. pylori infection can 
involve cardiovascular diseases, metabolic disorders, 
lung, hematologic and hepatobiliary diseases, gyne-
cologic diseases and neurologic diseases (Moyaert 
et al., 2008). With respect to metabolic disorders, H. 
pylori colonization is associated with reduced circu-
lating leptin levels, independent of body mass index 
(BMI),  while  fundic  ghrelin  and  leptin  levels  are 
directly related. Long-term eradication of H. pylori 
infection is associated with a significant increase in 
BMI, lean and fat mass, a decrease in circulating gh-
relin levels and an increase in leptin levels.
Non-pylori Helicobacter species (NPHS) in  
gastrointestinal diseases
H. heilmannii and H. felis have been rarely found in 
human stomach infections (Okoli et al., 2009). The 
gastritis observed with H. heilmannii infection tends 
to be less severe than that due to H. pylori. H. heil-
mannii has been found in association with duodenal 
ulceration, gastric ulceration, gastric carcinoma and 
mucosa-associated  lymphoid  tissue  (MALT)  lym-
phoma. A surprisingly high rate (3.4%) of MALT 
lymphomas  in  H.  heilmannii-infected  patients  has 
been noted (O’Rourke et al., 2001).
Helicobacters  cultured  from  human  diarrheal 
samples include H. cinaedi, H. canis, H. pullorum, 
H. fennelliae, H. canadensis, H. rappini and other un-
classified but related organisms. Despite all efforts to 
clarify their etiological role, it still remains vague. The 
data obtained by studying symptomatic and asympto-
matic homosexual males and experimental evidence 
on macaques implicate H. cinaedi and H. fennelliae in 
the etiology of human intestinal disease. H. pullorum 
and H. canadensis have been cultured from immu-
nocompetent and immunodeficient human patients 
presenting with acute or chronic diarrhea. H. rappini 
has been isolated in a gastroenteritis index case, his 
16-year-old asymptomatic daughter and a pet puppy. 
In addition, H. canis has been isolated from a child 
suffering from gastroenteritis and in fecal samples 
from healthy and diarrheic dogs. H. pullorum and H. 
canadensis have been cultured from immunocompe-
tent and immunodeficient human patients present-
ing with acute or chronic diarrhea (O’Rourke et al., 
2001).
Intestinal  Helicobacter  species  can  enter  the 
bloodstream, and it would therefore be expected 
that it could enter the liver. Despite detection of 
helicobacter 16s rDNA in liver tissues by PCR, there 
have been no published data of helicobacter cultiva-
tion or ultrastructural identification. The results of 
studies have often been conflicting and it seems that 
differences are related to geographic origin of the 
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Murine models have clearly shown that if the 
normal immune balances are altered then mucosa-
associated Helicobacter species can induce pathology 
similar to human IBD. This is possibly due to their 
location in mucous, the microbial niche closest to 
the susceptible mucosa. Whether an analogous proc-
ess occurs in humans is unclear. Helicobacter species 
have  not  consistently  been  isolated  from  IBD  pa-
tients. The presence of non-pylori Helicobacter spe-
cies in the human colon is unknown as this ecologi-
cal niche has been poorly studied (O’Rourke et al., 
2001).
NPHS in systemic disorders
There  have  been  numerous  reports  of  bacteremia 
associated with Helicobacter species with several re-
ports of recurrent infections. H. cinaedi and H. rap-
pini are the organisms most frequently cultured from 
blood. The majority of cases occurred in patients in-
fected with HIV, and having other predisposing fac-
tors such as alcoholism, end stage renal failure, car-
cinoma, diabetes, and primary immunodeficiencies: 
X-linked  agammaglobulinemia  and  hypogamma-
globulinemia. Helicobacter have also been isolated 
in pediatric bacteremia and, surprisingly, in healthy 
immunocompetent  adults.  The  secondary  sites  of 
infection reported with helicobacter bacteremia in-
clude abdominal abscess, cellulitis, septic arthritis, 
meningitis, and pneumonia (O’Rourke et al., 2001).
Helicobacter detection and typing methods
There are numerous tests for the detection of H. py-
lori infection. At present, priority is given to the de-
velopment and improvement of non-invasive tech-
niques. Nevertheless, invasive tests are first applied 
for H. pylori detection. The gold standard in H. pylori 
diagnosis is gastric intubation, endoscopy and bi-
opsy of gastric mucosa samples. H. pylori molecular 
identification methods can be applied for detection 
of virulence factors (Wen et al., 2007) and identifica-
tion of macrolide resistance (Megraud, 2007).
Contemporary  H.  pylori  typing  methods  are 
MLST, polymerase chain reaction – restriction frag-
ment length polymorphism (PCR-RFLP), AFLP, arbi-
trarily primed (AP)-PCR, repetitive extragenic palin-
dromic DNA sequence-based PCR (REP-PCR), type 
specific PCR (vacA, iceA, BabA, 23S allels), PCR-line 
probe assay LiPA (PCR-LiPA), restriction endonucle-
ase analysis (REA), PFGE, ribotyping, CagA detec-
tion, IS605/606 detection, and plasmid profile analy-
sis (Owen et al., 2001). Genomic methylation typing 
is useful to type bacteria that have a high number of 
expressed type II methyltransferases (MTase), such 
as H. pylori. Due to the type II restriction-and-mod-
ification (R-M) systems after acquisition, and due to 
the diversity of R-M systems in H. pylori, MTase from 
R-M systems was successfully used in the typing of H. 
pylori strains (Vale and Vítor, 2007).
A proteomic approach can be used in the iden-
tification  of  disease-specific  bacterial  biomarkers, 
targets for vaccines and serological diagnosis tests 
in H. pylori clinical isolates, throughout two dimen-
sional electrophoresis (2DE) analyses, followed by 
mass spectrometry (MS) protein identification. The 
enhanced virulence of pediatric ulcerogenic strains 
results from a synergy between their natural ability 
to better adapt to the hostile human stomach and the 
expression of the established virulence factors (Vito-
riano et al., 2011). Furthermore, studying the immu-
noproteome evidence has showed the variability of 
the antigenic pattern among H. pylori strains, which 
is the unusual extent of genetic heterogeneity that 
characterizes H. pylori, due to the unusually high 
rates of mutation and recombination events that oc-
cur in vivo (De Reuse et Bereswill, 2007).
CONCLUDING REMARKS
The  order  Campylobacterales  is  comprised  of  two 
families: Helicobacteraceae and Campylobacteraceae. 
These are Gram-negative, spiral, helical, microaer-
ophilic organisms with optimal growth temperature 
at 37 oC for H. pylori, and 42oC for C. jejuni strains. 
Both genera can be represented in mammals, includ-
ing humans and birds as reservoirs. Diseases caused 
by C. jejuni are almost exclusively observed in hu-
mans, and H. pylori invades almost exclusively the 
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the etiology of gastric disorders, Campylobacter and 
NPHS in the etiology of diarrhea, while C. jejuni and 
H. pylori play roles in the etiology of immunopro-
liferative diseases, inflammatory bowel disease and 
autoimmunity.
Different clinical presentations of human disor-
ders may be the consequences of the differences in 
the host’s immune responses and bacterial endotoxin 
activity (Moran, 2010). Since H. pylori endotoxin ex-
pressed  underphosphorylation  and  underacylation 
of the lipid A, it has lower endotoxic activity and in-
teraction with immune receptors is significantly low-
er, which may lead to the prolongation of H. pylori 
infection and chronicity. C. jejuni endotoxin is im-
munologically and endotoxically more active, thus 
contributing  to  diarrhea  and  acute  inflammation 
(Moran,  2010).  Moreover,  flagellar  proteins  from 
both bacteria are defective in TLR5 activation.
However, both H. pylori and C. jejuni possess 
molecules that express cross-reactive epitopes with 
human tissue. H. pylori expresses mimicry of Lewis 
and some ABO blood group antigens involved in in-
flammation, gastric atrophy, and cancerogenesis. C. 
jejuni exhibits mimicry of gangliosides, crucial for 
the development of the GBS and MFS. It is possible 
that an innovative approach in strain characterization 
could be applied to describe both genera and would 
reveal more similarity than originally perceived or 
better explain the observed differences. 
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